Table 2.
Details of the line of anti-PD-1 therapy, duration of treatment, survival, and subsequent treatment on progression.
| PN | Anti-PD-1 Therapy | Line of anti-PD-1 therapy | ECOG PS | Response | DOT (months) | PFS (months) | TPTD (months) | Overall Survival (months) | Subsequent therapy |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Pembrolizumab | second | 1 | PR | 4.1 | 24.6 | 20.5 | 39.3∗ | Radiation, pembrolizumab with development of pembrolizumab induced psoriasis |
|
| |||||||||
| 2 | Pembrolizumab | second | 0 | CR | 4.6 | 20.2 | 15.6 | 49.0∗ | Radiation, pembrolizumab with TLR9 agonist without immune toxicities |
|
| |||||||||
| 3 | Nivolumab | second | 1 | CR | 2.6 | 49.4+ | 46.8+ | 49.4∗ | NA |
|
| |||||||||
| 4 | Pembrolizumab | first | 1 | SD | 2.3 | 3.0 | 0.7 | 4.6 | Dabrafenib with trametinib |
|
| |||||||||
| 5 | Pembrolizumab | second | 0 | PR | 3.5 | 30.3+ | 26.9+ | 30.3∗ | NA |
|
| |||||||||
| 6 | Pembrolizumab | second | 1 | CR | 11.5 | 36.3+ | 24.8+ | 36.3∗ | NA |
|
| |||||||||
| 7 | Pembrolizumab | first | 1 | PR | 4.8 | 18.1 | 13.3 | 23.4 | Radiation |
|
| |||||||||
| 8 | Pembrolizumab | second | 1 | SD | 4.8 | 7.3 | 2.6 | 28.3∗ | Craniotomy and surgical resection, stereotactic radiosurgery, vemurafenib with cobimetinib |
|
| |||||||||
| 9 | Pembrolizumab | first | 0 | CR | 6.5 | 17.5+ | 11.0+ | 17.5∗ | NA |
|
| |||||||||
| 10 | Pembrolizumab | first | 1 | CR | 6.9 | 21.9+ | 15.0+ | 21.9∗ | NA |
|
| |||||||||
| 11 | Pembrolizumab | first | 0 | CR | 9.7 | 30.1+ | 20.5+ | 30.1∗ | NA |
|
| |||||||||
| 12 | Pembrolizumab | first | 0 | CR | 0.7 | 23.0+ | 22.3+ | 23.0∗ | NA |
|
| |||||||||
| 13 | Pembrolizumab | second | 2 | PR | 4.6 | 16.8 | 12.2 | 25.0∗ | Radiation, dabrafenib with trametinib |
|
| |||||||||
| 14 | Pembrolizumab | first | 0 | PR | 5.0 | 19.3 | 14.3 | 31.8 | Pembrolizumab with TLR9 agonist without immune toxicity, radiation, vemurafenib with cobimetinib |
|
| |||||||||
| 15 | Pembrolizumab | third | 1 | CR | 11.5 | 37.3+ | 25.8+ | 37.3∗ | NA |
|
| |||||||||
| 16 | Pembrolizumab | first | 0 | PD | 1.3 | 1.6 | 0.2 | 5.4 | Temozolomide |
PN: patient number. ECOG PS: Eastern Cooperative Oncology Group Performance Status.
PR: partial response. CR: complete response. ∗Alive.
SD: stable disease. PD: progressive disease. +-Censored, no evidence of progression.
DOT: Duration of treatment.
TPTD: time to progression from treatment discontinuation.